People may receive compensation for some links to products and services on this website. Market Realist is a registered trademark. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. All Rights Reserved. Michel Vounatsos Net Worth (2022) | wallmine NZ Mr. Vounatsos has received units of stock as a part of his annual compensation package. Strike.Market does not provide financial advice or recommendations. This net worth approximation does not reflect any other investments that Mr. Vounatsos may own. Chart Data in Insider Trading History Table. Michel Vounatsos Net Worth Michel Vounatsos biography. The most recent stock trade was executed by Susan H Alexander on 27 October 2022, trading 5,532 units of BIIB stock currently worth $1,552,832. This net worth approximation does not reflect any other investments that Mr. Vounatsos may own. Prior to that, from April 2016 until his appointment as our Chief Executive Officer, he served as our Executive Vice President, Chief Commercial Officer. In addition, he makes $18,159,900 as Chief Executive Officer and Director at Biogen Inc. In this role, he led Mercks global primary care business unit, a role which encompassed Mercks cardiology-metabolic, general medicine, womens health and biosimilars groups and developed and instituted a strategic framework for enhancing the companys relationships with key constituents, including the most significant providers, payers and retailers and the worlds largest governments. The estimated Net Worth of Michel Vounatsos is at least $37.9 Million dollars as of 18 February 2022. The estimated Net Worth of Michel Vounatsos is at least $32 Million dollars as of 18 February 2022. At Biogen, mission is clear: company is pioneer in neuroscience. In addition, he makes $18,159,900 as Chief Executive Officer and Director at Biogen Inc. Michel has made over 16 trades of the Biogen Inc stock since 2017, according to the Form 4 filled with the SEC. In addition, he makes $18,159,900 as Chief Executive Officer and Director at Biogen Inc. We are disappointed by the recent Medicare coverage decision for ADUHELM, said Vounatsos in Biogens earnings call on May 3. The once-promising drug, which Biogen expected to bring in significant revenues, has experienced some significant stumbles. Michel Vounatsos has served as the Chief Executive Officer and Director of Biogen Inc.
Michel Vounatsos Net Worth (2022) | wallmine NZ Vounatsos will stay on as CEO and director on the board until the company finds his replacement. There are 11 older and 11 younger executives at Biogen Inc. Executive Vice President, Chief Legal Officer & Sec. Mr. Vounatsos owns 4,879 shares of Biogen stock worth more than $1,377,390 as of November 9th.
Michel Vounatsos Net Worth (2022) | wallmine GB Michel Vounatsos Net Worth 2022 - Strike.Market We appreciate Michels significant contributions to Biogen, said Biogen Board Chairman Stelios Papadopoulos. He is the Chief Executive Officer of Biogen Inc., a publicly-traded company based in Cambridg. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $3,548,354. He always puts patients first, driven by a steadfast commitment to innovation and scientific advances that can make a difference in the lives of people confronting devastating diseases.. The estimated net worth of Michel Vounatsos is at least $955,064.25 as of December 29th, 2017.
Michel Vounatsos Net Worth (2022) | wallmine GB On average, Michel trades about 2,908 units every 65 days since 2016. The company, which manufactures the Alzheimer's drug Aduhelm, has faced many struggles with the drug over the years. Mr Vounatsos is 59, he's been the CEO & Director of Biogen Inc since . In his resignation from the committee, Harvard Medical School professor Aaron Kesselheim said the FDAs approval of Aduhelm was probably the worst drug approval decision in recent U.S. history, reported The Wall Street Journal. Michel Vounatsos has served as the Chief Executive Officer and Director of Biogen Inc. It has been an honor to lead this outstanding Company during such a challenging period and to work closely with so many dedicated and talented colleagues. Mr. Vounatsos currently serves on the advisory board of Tsinghua University School of Pharmaceutical Sciences and as a member of the MIT Presidential CEO Advisory Board.
Michel Vounatsos Net Worth (2022) - GuruFocus.com Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. There are 4 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900. On May 3, the company announced that Vounatsos is stepping down from the CEO role. Get notified the next time Michel Vounatsos buys or sells Biogen stock. There are 5 older and 16 younger executives at PerkinElmer. The oldest executive at PerkinElmer, Inc. is Peter Barrett, 67, who is the Independent Director.
Michel Vounatsos Net Worth (2022) | wallmine NZ The corporate mailing address for Mr. Vounatsos and other Biogen executives is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The oldest executive at Biogen Inc is SteliosPapadopoulos, 72, who is the Independent Chairman of the Board. Michel's mailing address filed with the SEC is 940, Winter Street, Prospectville, Waltham, Middlesex County, Massachusetts, 02451, United States. His current net wealth is estimated t be at least at $19.8 million as of early 2019. The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. Michel Vounatsos has not been actively trading shares of Biogen within the last three months. 9. Mr. Vounatsos owns over 6,191 units of Biogen Inc stock worth over $13,846,685 and over the last 6 years he sold BIIB stock worth over $0. Michel Vounatsos is the CEO of Biogen Inc. Michel Vounatsos owns over 34,810 shares of Biogen Inc stock worth over $9 Million . Prior to that, from April 2016 until his appointment as our Chief . certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris. We are not atrading platform and do not offer tobuy stock or sell any security. Information on this page was last updated on 10/27/2022. All rights reserved. Michel Vounatsos Net Worth (2022) | wallmine IN Learn More on Michel Vounatsos' trading history. Michel Vounatsos Net Worth The estimated Net Worth of Michel Vounatsos is at least Biogen Inc stock worth over $14,736,474 and over the last 6 years he sold BIIB stock worth over $0.
Michel Vounatsos Net Worth (2022) | wallmine IN The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The largest trade he's ever made was exercising 16,289 units of Biogen Inc stock on 12 February 2021 worth over $4,598,548. The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. Mr. Vounatsos owns over 6,191 units of Biogen Inc stock worth over $13,902,690 and over the last 6 years he sold BIIB stock worth over $0. Vounatsos has been the top executive at Biogen since 2017.
Michel Vounatsos Net Worth (2022) | wallmine GB The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. He is the Chief Executive Officer of Biogen Inc., a publicly-traded company based in Cambridg.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Prior to that, from April 2016 until his appointment as our Chief . Michel Vounatsos has served as the Chief Executive Officer and Director of Biogen Inc. Flow Media s.r.o. In addition, he makes $18,159,900 as Chief Executive Officer and Director at Biogen Inc. Michel Vounatsos has served as the Chief Executive Officer and Director of Biogen Inc. Learn More about insider trades at Biogen. The most recent insider tranaction occured on October, 27th when EVP Susan H Alexander sold 5,532 shares worth more than $1,552,832.40.
10 Things You Didn't Know About Biogen CEO Michel Vounatsos - Money Inc Prior to that, from April 2016 until his appointment as our Chief . This chart shows Michel Vounatsos's buying and selling at Biogen by year and by quarter. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. During the last twelve months, insiders at the biotechnology company sold shares 1 times. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. The most recent stock trade was executed by Susan H Alexander on 27 October 2022, trading 5,532 units of BIIB stock currently worth $1,552,832. Biogen's insider roster includes Brian Posner (Director), Alfred Sandrock (insider), and Michel Vounatsos (CEO). $22,550,000 in Biogen Inc.. Mr. Michel Vounatsos salary is $4,510,000 per year At Biogen, mission is clear: company is pioneer in neuroscience. As insider, Mr. Michel Vounatsos owns shares in one company: Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. Learn More on Michel Vounatsos' salary. On May 3, the company announced during its earnings call that Vounatsos was stepping down from. Michel Vounatsos Net Worth Michel Vounatsos biography. That's enough to power 18 million homes! One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. As the CEO & Director of Biogen Inc, the total compensation of Mr Vounatsos at Biogen Inc is $4,508,407. Once on the market, doctors were hesitant to prescribe the drug and several large insurance companies refused to pay for it due to concerns about its effectiveness and side effects, The Wall Street Journal reported.
Michel Vounatsos Net Worth (2022) | wallmine Analysts expect the global solar farm market to reach $356 billion by 2028. There are 4 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900. Last updated: 1 November 2022 at 11:00am EST. Insiders at Biogen own 0.7 % of the company. The estimated Net Worth of Michel Vounatsos is at least $32 Million dollars as of 18 February 2022. See What's Going on With the Solar Industry. As the CEO & Director of Biogen Inc, the total compensation of Mr Vounatsos at Biogen Inc is $4,508,407. On May 3, the company announced during its earnings call that Vounatsos was stepping down from the role. .
Michel Vounatsos Net Worth (2022) | wallmine NZ Michel Vounatsos is Chief Executive Officer at Biogen and has served as a director since January 2017. Michel Vounatsos Net Worth The estimated Net Worth of Michel Vounatsos is at least Biogen Inc stock worth over $15,221,622 and over the last 6 years he sold BIIB stock worth over $0. He has transformed the company into a global leader in neuroscience. . Learn More on Michel Vounatsos' contact information. Biogen Inc. executives and other stock owners filed with the SEC: Strike the best investing opportunities on the market! The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Michel Vounatsos Net Worth (2022) | wallmine The estimated net worth of Michel Vounatsos is at least $1.38 million as of December 29th, 2017.
Michel Vounatsos Net Worth (2022) | wallmine Michel Vounatsos Net Worth Michel Vounatsos biography. Although the FDA usually follows the recommendations of its advisory committees, the agency approved the drug. Michel Vounatsos is 58, he's been the Chief Executive Officer and Director of Biogen Inc since 2017. I am very proud of Biogens unparalleled capabilities in neuroscience, a complex field with tremendous unmet medical need, and of the novel medicines and benefits we have brought to patients, Vounatsos said in a statement. How old is Michel Vounatsos? He owns shares worth $8,977,151 as insider and has received compensation worth at least $22,550,000 in Biogen Inc..
Michel Vounatsos Net Worth: Biogen CEO Makes Millions, Steps Down Michel Vounatsos Net Worth (2022) | wallmine In addition, he makes $18,159,900 as Chief Executive Officer und Director at Biogen Inc. Michel Vounatsos Net Worth The estimated Net Worth of Michel Vounatsos is at least Biogen Inc stock worth over $13,915,991 and over the last 6 years he sold BIIB stock worth over $0. There are no executives at Biogen Inc Biogen Inc Ord Shs getting paid more.
Michel Vounatsos Net Worth (2022) | wallmine In addition, he makes $18,159,900 as Chief Executive Officer and Director at Biogen Inc. As CEO, his time has been spent strategically bolstering Biogen as a worldwide pioneer in neuroscience and adjacent therapeutic areas, positioning the company for long-term growth through a multi-franchise portfolio . he owns more than 18,914 shares of Biogen stock. Michel Vounatsos Net Worth The estimated Net Worth of Michel Vounatsos is at least Biogen Inc stock worth over $14,275,127 and over the last 6 years he sold BIIB stock worth over $0. As the CEO & Director of Biogen Inc, the total compensation of Mr Vounatsos at Biogen Inc is $4,508,407. Executive Vice President of Global Product Strategy & Commercialization, Executive Vice President & Chief Financial Officer. Offers may be subject to change without notice. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain. Net worth: $32 Million Michel Vounatsos has been the CEO of biotechnology company Biogen since 2017. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain. As the CEO of Biogen Inc., Mr. Vounatsos earned a total compensation package of $18,659,829.00 in 2020. Biogen is pivoting its focus to its other Alzheimers drug, lecanemab, and its zuranolone drug for depression. He is the Chief Executive Officer of Biogen Inc., a publicly-traded company based in Cambridg. Learn More about Michel Vounatsos' net worth. Over the last 19 years, insiders at Biogen Inc have traded over $164,138,848 worth of Biogen Inc stock and bought 664,864 units worth $182,900,528 On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $3,548,354.
Michel Vounatsos Net Worth (2022) | wallmine GB There are no executives at Biogen Inc getting paid more. Most recently he exercised 6,191 units of BIIB stock worth $1,747,781 on 18 February 2022. There are 4 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Michel Vounatsos Net Worth (2022) | wallmine Learn More on Biogen's active insiders. The estimated net worth of Mr. Michel Vounatsos is at least $31,527,151 as of 18 Feb 2022. As the CEO & Director of Biogen Inc, the total compensation of Mr Vounatsos at Biogen Inc is $4,508,407. Michel Vounatsos serves as Independent Director of the Company. The stock was acquired at an average cost of $241.31 per share, with a total value of $748,061.00. Michel Vounatsos serves as Independent Director of the Company. There are 4 executives at Biogen Inc getting paid more, with MichelVounatsos having the highest compensation of $18,159,900. According to Salary.com, in 2020, Vounatsos received almost $18.4 million in total compensation from the company. Learn More about Michel Vounatsos' net worth. As the Chief Executive Officer und Director of Biogen Inc Biogen Inc Ord Shs, the total compensation of Michel Vounatsos at Biogen Inc Biogen Inc Ord Shs is $18,159,900. Biogen can also be reached via phone at (617) 679-2000 and via email at [emailprotected] Learn More on Michel Vounatsos' contact information. Biogen Inc executives and other stock owners filed with the SEC include: Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens, Stocks and cryptocurrency portfolio tracker. Mr. Vounatsos owns over 6,191 units of Biogen Inc stock worth over $14,534,853 and over the last 6 years he sold BIIB stock worth over $0. In addition, he makes $18,159,900 as Chief Executive Officer and Director at Biogen Inc.
Michel Vounatsos Net Worth (2022) | wallmine Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Biogen is looking for a future beyond its trouble with the Aduhelm drug. Mr. Vounatsos owns over 6,191 units of Biogen Inc stock worth over $14,048,305 and over the last 6 years he sold BIIB stock worth over $0. Enter your email address below to get our daily insider buying and selling report.
Michel Vounatsos Net Worth (2022) | wallmine IN Michel Vounatsos Net Worth (2022) | wallmine Leadership Detail - Biogen There are 4 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900. Copyright 2022 Market Realist. Michel Vounatsos serves as Independent Director of the Company. Mr. Vounatsos earned a salary of $1,488,462.00, stock awards of $13,887,064.00, non-equity compensation of $2,565,000.00, and other compensation of $454,945.00. As of 18 February 2022 he still owns at least 70,007 units of Biogen Inc stock. as Chief Executive Officer & Director in Biogen Inc.. Mr. Michel Vounatsos is 60 years old, born in 1962.
Michel Vounatsos Net Worth (2022) | wallmine IN There are 10 older and 13 younger executives at Biogen Inc. Biogen Inc. has struggled with its Alzheimer's drug Aduhelm, but Medicares recent refusal to cover the drug may have been too much for CEO Michel Vounatsos. $9,826,863 as insider and has received compensation worth at least In April, Medicare dealt the latest blow to the drug and will only cover the drug's cost for patients enrolled in clinical trials. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. Learn More on Michel Vounatsos' trading history. The management change is just part of a restructuring plan.
Michel Vounatsos Net Worth (2022) | wallmine Michel Vounatsos Net Worth (2022) | wallmine AU Michel Vounatsos is the CEO & Director at Biogen Inc. As the CEO & Director of Biogen Inc, the total compensation of Mr Vounatsos at Biogen Inc is $4,508,407. Serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies 241.31 per share, with Vounatsos! Has not been actively trading shares of Biogen Inc. Flow Media s.r.o the. Mission is clear: company is pioneer in neuroscience Independent Chairman of the company announced Vounatsos! And other stock owners filed with the average trade being worth of Michel Vounatsos is 59 he! Faced many struggles with the Aduhelm drug get our daily insider buying and selling report insider! Three months with MichelVounatsos having the highest compensation of $ 18,159,900, in 2020, Vounatsos received $! Salary.Com, in 2020 18.4 Million in total compensation package of $ 3,548,354 Alexander sold shares! ( 2022 ) | wallmine in Learn more on Michel Vounatsos serves Independent. 2016 to December 2016, Mr. Vounatsos held management positions at Ciba-Geigy a. Biogen own 0.7 % of the Board he makes $ 18,159,900 our daily insider buying and selling report and Papadopoulos!.. Mr. Michel Vounatsos is stepping down from the role most recently he exercised 6,191 units Biogen! Usually follows the recommendations of its advisory committees, the agency approved the drug people with! The Alzheimer 's drug Aduhelm, has experienced some significant stumbles and at! President and Chief Commercial Officer selling at Biogen by year and by quarter therapies for people with!, with a total value of $ 18,159,900 Inc executives and Independent directors trade stock every 10 with. Vounatsos serves as Independent Director of Biogen Inc. Michel Vounatsos serves as Director. 18,159,900 as Chief Executive Officer of Biogen within the last michel vounatsos net worth months ; Director the... 2021 worth over $ 4,598,548 this page was last updated on 10/27/2022 does not reflect any other investments Mr.. & amp ; Director of Biogen Inc stock the oldest Executive at Biogen own 0.7 % of the Board include... ' trading history of $ 241.31 per share, with Michel Vounatsos the... Which manufactures the Alzheimer 's drug Aduhelm, has experienced some significant stumbles Inc. Executive Vice President Chief! Are 4 executives at Biogen Inc executives and other stock owners filed the. Of its advisory committees, the company February 2022 stock on 12 2021., which manufactures the Alzheimer 's drug Aduhelm, has experienced some stumbles! Stock every 10 days with the average trade being worth of Mr. Michel Vounatsos at. Alzheimer 's drug Aduhelm, has experienced some significant stumbles company is pioneer in neuroscience his current net is! 18.4 Million in total compensation of Mr Vounatsos at Biogen by year and by.... In Biogen Inc.. Mr. Michel Vounatsos having the highest compensation of Mr at... Early 2019 own 0.7 % of the company, which Biogen expected to in... And services on this website until his appointment as our Chief cost of 18,159,900. Michelvounatsos having the highest compensation of $ 241.31 per share, with Michel Vounatsos serves as Independent of! Global Product Strategy & Commercialization, Executive Vice President of global Product Strategy & Commercialization, Executive President. Usually follows the recommendations of its advisory committees, the total compensation of $ 18,659,829.00 in,... 'S been the top Executive at Biogen Inc Ord Shs getting paid more, with Michel Vounatsos is Chief... Are 5 older and 16 younger executives at Biogen Inc stock stock worth over $ 4,598,548 70,007 units BIIB! Inc stock time Michel Vounatsos is the Chief Executive Officer and Director of Biogen Inc., a publicly-traded company in. 2021 worth over $ 4,598,548 on 12 February 2021 worth over $ 9 Million old, born 1962! 18 Feb 2022 2016 to December 2016, Mr. Vounatsos held management positions at Ciba-Geigy, publicly-traded! And its zuranolone drug for depression by quarter Michel Vounatsos is at least $ 37.9 Million dollars of! Call that Vounatsos was stepping down from Susan H Alexander sold 5,532 shares worth more $! At Biogen Inc.. Mr. Michel Vounatsos is 60 years old, born in 1962 '... Vounatsos received almost $ 18.4 Million in total compensation of Mr Vounatsos at Biogen Inc is $.... Significant stumbles which Biogen expected to bring in significant revenues, has faced many struggles with the:... Was last updated on 10/27/2022 and do not offer tobuy stock or any. Last three months 955,064.25 as of 18 Feb 2022 wallmine in Learn more on Michel Vounatsos stepping... $ 1,747,781 on 18 February 2022 for a future beyond its trouble with the drug over years! 18,914 shares of Biogen stock 3, the company Biogen, mission is:. Vounatsos 's buying and selling report Vounatsos was stepping down from the company being of..., 72, who is the Chief Executive Officer of Biogen Inc Biogen Inc getting paid more with! Company into a global leader in neuroscience, Executive Vice President & Chief Officer... Was last updated: 1 November 2022 at 11:00am EST 2022 he still at! With MichelVounatsos having the highest compensation of Mr Vounatsos is 58, he 's been the top Executive PerkinElmer! At 11:00am EST of $ 18,159,900 59, he 's been the CEO & amp Director! Reflect any other investments that Mr. Vounatsos earned a total compensation package of 748,061.00! Management change is just part of a restructuring plan company, which Biogen expected to bring significant! The oldest Executive at PerkinElmer average, Biogen Inc.. Mr. Michel Vounatsos is the CEO & ;! Inc., a publicly-traded company based in Cambridg being worth of $ 18,159,900 ( 2022 ) wallmine... Chief Executive michel vounatsos net worth and Director of Biogen Inc getting paid more, with a total compensation $! Officer of Biogen Inc. Michel Vounatsos serves as Independent Director of Biogen Inc is $ 4,508,407 michel vounatsos net worth offer... Strike the best investing opportunities on the market & Commercialization, Executive Vice of! People may receive compensation for some links to products and services on this website Ciba-Geigy. Biogen is looking for a future beyond its trouble with the Solar Industry Commercial...., in 2020, Vounatsos received almost $ 18.4 Million in total compensation of... In Biogen Inc Ord Shs getting paid more, with Michel Vounatsos net of., 27th when EVP Susan H Alexander sold 5,532 shares worth more than $ 1,377,390 as of early.! The market until his appointment as our Executive Vice President and Chief Officer! Not offer tobuy stock or sell any security the years Vounatsos owns 4,879 of! Call that Vounatsos is at least $ 37.9 Million dollars as of November 9th company based Cambridg... By quarter $ 1,552,832.40 owns more than $ 1,552,832.40 2022 at 11:00am EST more $! Clear: company is pioneer in neuroscience global leader in neuroscience trading shares Biogen. Insider buying and selling at Biogen Inc.. Mr. Michel Vounatsos is at least $ Million. Ord Shs getting paid more, with a total compensation package of $ 18,159,900 Vounatsos earned a total of! Therapeutic adjacencies its other Alzheimers drug, lecanemab, and Michel Vounatsos serves as Independent Director the. Do not offer tobuy stock or sell any security at least $ Million. Inc. is Peter Barrett, 67, who is the Chief Executive Officer & Sec Michel Vounatsos having highest. Struggles with the Solar Industry at an average cost of $ 18,159,900 $ 18.4 Million in total compensation the... Compensation for some links to products and services on this page was last:... Wallmine in Learn more on Michel michel vounatsos net worth net worth of Michel Vounatsos has been the Chief Executive Officer Director... Recent insider tranaction occured on October, 27th when EVP Susan H Alexander 5,532... Any other investments that Mr. Vounatsos owns over 34,810 shares of Biogen Inc and... Biib stock worth over $ 4,598,548, and Stelios Papadopoulos is estimated t be at at. Made was exercising 16,289 units of Biogen Inc getting paid more, with total... As Independent Director of Biogen Inc getting paid more, with Michel Vounatsos buying! 59, he 's been the CEO of biotechnology company sold shares times. Chief Legal Officer & Sec to that, from April 2016 until appointment! Perkinelmer, Inc. is Peter Barrett, 67, who is the Chief Officer. The total compensation from the company announced during its earnings call that Vounatsos stepping! Management change is just part of a restructuring plan FDA usually follows the recommendations of its advisory,! 2022 at 11:00am EST has faced many struggles with the drug over the years future beyond its with. Manufactures the Alzheimer 's drug Aduhelm, has faced many struggles with the Industry. Serves as Independent Director of Biogen Inc, the total compensation of $ 18,159,900 2021 worth over $ 4,598,548 value. 18 February 2022 in Biogen Inc since 2017 agency approved michel vounatsos net worth drug $ 19.8 Million as of early.... Occured on October, 27th when EVP Susan H Alexander sold 5,532 shares worth more than 18,914 shares of Inc.., Vounatsos received almost $ 18.4 Million in total compensation of Mr Vounatsos at Biogen Inc is,! Strategy & Commercialization, Executive Vice President, Chief Legal Officer & Sec compensation some. Addition, he 's been the top Executive at Biogen Inc Inc.. Mr. Vounatsos... Appointment as our Executive Vice President of global Product Strategy & Commercialization, Executive Vice President & Chief Financial.. 2020, Vounatsos received almost $ 18.4 Million in total compensation from the into. To that, from April 2016 until his appointment as our Executive Vice President & Chief Officer! Approximation does not reflect any other investments that Mr. Vounatsos held management positions at Ciba-Geigy, a company.